Wos İndeksli Yayınlar Koleksiyonu

Permanent URI for this collectionhttps://hdl.handle.net/11727/4807

Browse

Filters

2015 - 201912020 - 20221

Settings

search.filters.applied.f.language: search.filters.language.turSubject: search.filters.subject.therapy

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Heart failure with non-reduced ejection fraction: Epidemiology, pathophysiology, phenotypes, diagnosis and treatment approaches
    (2022) Cavusoglu, Yuksel; Celik, Ahmet; Altay, Hakan; Nalban, Sanem; Ozden, Ozge; Temizhan, Ahmet; Ural, Ditek; Unlu, Serkan; Yilmaz, Mehmet Birhan; Zoghi, Mehdi; 35969235
    Heart failure (HF) has been classified as reduced ejection fraction (HFrEF), mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) by the recent HF guidelines. In addition, HF with improved ejection fraction has been defined as a subgroup of HFrEF. In HFrEF, diagnostic workup and evidence-based pharmacological and device-based therapies have been well established. However, HFpEF, which comprises almost half of the HF population, represents significant uncertainties regarding its pathophysiology, clinical phenotypes, diagnosis and treatment. Diagnostic criteria of HFpEF have been changed a few times over the years and still remained a matter of debate. New paradigms including a prominent role of co-morbidities. inflammation, endothelial dysfunction have been proposed in its pathophysiology. As a complex, multifactorial syndrome HFpEF consists of many overlapping clinical and hemodynamic phenotypes. In contrast to HFrEF, clinical outcomes of HFpEF have not improved over the last decades due to lack of proven effective therapies. Although HFrEF and HFpEF have different clinical spectrums and proposed pathophysiological mechanisms, there is no clear defining syndrome postulated for HFmrEF. Clinical characteristics and risk factors of HFmrEF overlap with HFrEF and HFpEF. HFmrEF is also referred as a transitional zone for dynamic temporal changes in EF. So. HFpEF and HFmrEF, both namely HF with non-reduced ejection fraction (HF-NEF), have some challenges in the management of HF. The purpose of this paper is to provide a comprehensive review including epidemiology, pathophysiology, clinical presentation and phenotypes of HF-NEF and to guide clinicians for the diagnosis and therapeutic approaches based on the available data in the literature.
  • Thumbnail Image
    Item
    The Diagnosis and Treatment of Retroperitoneal Mass
    (2015) Gul, Umit
    Retroperitoneal masses are extremely rare. They may be primary malignant, benign or metastatic. The majority of them are malignant. Possible causes that may reveal the etiology of these masses have not been clarified yet. However some predisposing factors have been identified. These masses are classified according to their histological types. Clinical signs are presence of abdominal mass and abdominal pain. A multidisciplinary approach for diagnosis and treatment in high-volume referral centers is ideal. Retroperitoneal masses are treated surgically as much as possible. It is important to achieve negative surgical margins. Optimal treatment approaches have not been standardized as of today. Anthracycline chemotherapy which may be combined with radiotherapy forms the basis of therapy. Developments related to targeted therapies are particularly promising.